RKDA
Arcadia Biosciences, Inc.
Set alert
0.16 USD -0.01 -7.39%
0.1368 Day range 0.166
0.145 52-week range 3.90
- YTD
- -92.03%
- 1 year
- -95.74%
- Open
- 0.152
- Prev close
- 0.1705
- Mkt cap
- 380.41K
- Vol
- 847.42K
- Avg vol
- 1.91M
- EPS
- -4.55
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1368
- High
- 0.166
- Forward P/E
- -4.76
- Beta
- 0.00
- Short ratio
- 0.73
- Inst. own
- 4.70%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.09
- 200-d avg
- 3.03
- 1y target
- 9.00
Key statistics
- Market cap
- 8.31M
- Enterprise value
- 2.30M
- Trailing P/E
- 0.00
- Forward P/E
- -4.76
- PEG ratio
- 0.00
- Price / sales
- 1.60
- Price / book
- 0.81
- EPS (TTM)
- -6.77
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -112.42%
- Revenue (TTM)
- 5.18M
- Revenue growth
- -3.80%
- Free cash flow
- -7.37M
- Total cash
- 6.58M
- Total debt
- 346.00K
- Return on equity
- -52.65%
- Shares outstanding
- 1.36M
- Short % of float
- 0.67%
- 50-day average
- 4.09
- 200-day average
- 3.03
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 9.00 +5599.8% upside
Now 0.1579
- Target (low)
- 6.00
- Target (mean)
- 9.00
- Target (high)
- 12.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.50.
Financials — quick view
RKDA Revenue — quarterly 1.44M
RKDA Net income — quarterly -6.27M
RKDA EPS — quarterly -2.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.77 | -0.87 | -0.10 | -12.99% |
| Aug 13, 2024 | Jun 1, 2024 | 1.27 | 0.78 | -0.49 | -38.58% |
| May 9, 2024 | Mar 1, 2024 | -2.52 | -1.78 | +0.74 | +29.37% |
| Mar 28, 2024 | Dec 1, 2023 | -2.68 | -2.48 | +0.20 | +7.46% |
| Nov 9, 2023 | Sep 1, 2023 | -2.67 | -1.83 | +0.84 | +31.46% |
| Aug 10, 2023 | Jun 1, 2023 | -4.92 | -2.64 | +2.28 | +46.34% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 23, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 28, 2023 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 24, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Country
- United States
- Website
- arcadiabio.com
News
- Financial Comparison: Arcadia Biosciences (NASDAQ:RKDA) vs. Anheuser-Busch InBev SA/NV (NYSE:BUD)
- Arcadia Biosciences, Inc. (NASDAQ:RKDA) Short Interest Update
- Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
- Analyzing Arcadia Biosciences (NASDAQ:RKDA) & Molson Coors Beverage (NYSE:TAP.A)
- Arcadia Biosciences (NASDAQ:RKDA) and Kirin (OTCMKTS:KNBWY) Financial Survey
- 12 Consumer Staples Stocks Moving In Monday's After-Market Session
- 12 Consumer Staples Stocks Moving In Thursday's After-Market Session
- Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
- Arcadia Biosciences (NASDAQ:RKDA) versus Diageo (NYSE:DEO) Critical Comparison
- Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Your note
Sign in to keep a note on RKDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JACOT STANLEY JR | Chief Executive Officer | Purchase | May 29, 2023 | 5,000 |
| KAWAKAMI MARK | Chief Financial Officer | Purchase | Jul 31, 2024 | 1,981 |
| SCHAEFER THOMAS J. | Chief Financial Officer | Purchase | Aug 3, 2023 | 719 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mariner, LLC | 1.83% | 25,000 | 152.25K | Sep 29, 2024 |
| Vanguard Group Inc | 1.03% | 14,038 | 85.49K | Sep 29, 2024 |
| State Street Corporation | 0.89% | 12,146 | 73.97K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.13% | 1,764 | 10.74K | Sep 29, 2024 |
| Morgan Stanley | 0.04% | 607 | 3.70K | Sep 29, 2024 |
| UBS Group AG | 0.02% | 239 | 1.46K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.03% | 14,038 | 85.49K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.56% | 7,577 | 46.14K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 1,626 | 9.90K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 1,006 | 6.13K | Oct 30, 2024 |